For super-resolution microscopes, AI helps by restoring images from even noisy, low-fluorescence data. That capability helps ...

Below, CNBC Select explains the differences between trademarks, copyrights and patents. Read on for more information and to ...

The last two decades have not been kind to science studies. Already bruised and battered by the “science wars” of the 1990s, ...

APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 ('NK-1”) antagonist ...

Utilizing its innovative ADC payload platform, Akari is advancing a new class of immuno-oncology ADCs built on the platform of a novel PH1 payload. This payload is designed specifically to target and ...

Genpact , an agentic and advanced technology solutions company, today announced its recognition as a Horizon 3 Market Leader in the HFS Horizons: Intelligent Supply Chain Services, 2025 assessment.

Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.

Despite the importance of GoF modifications, they have sometimes faced misplaced concerns or opposition that could lead to their being overregulated or even banned.

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic ...

MassBay Community College will hold its biannual Student STEM Expo on Wednesday, December 10, 2025, from 1:00 p.m. – 2:00 p.m. in the Wellesley Hills campus cafeteria, as well as virtually from Monday ...

Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty ...